omeprazole is an effective and well-known proton pump inhibitor used to treat a variety of gastrointestinal conditions. Owned by Dexcel Pharma, this drug with the active ingredient omeprazole was first authorized for market use on 04 December, 2007. It is available in tablet form with delayed release; oral dosage. Till date, omeprazole holds a total of 3 drug patents.
Though Omeprazole has 3 patents, none of them have expired yet. The patent with the most influence on the release of generic versions of Omeprazole is US10076494, titled 'Stable orally disintegrating pharmaceutical compositions', which is due to expire on 08 December, 2036. Therefore, the entry of Omeprazole generic into the market is strictly tied to the expiration of this patent.
omeprazole is widely used to treat conditions caused by excess stomach acid such as gastroesophageal reflux disease (GERD), ulcers of the stomach and small intestine, and Zollinger-Ellison Syndrome. It works by blocking the production of acid in the stomach, which reduces heartburn and helps heal the stomach lining.
Omeprazole holds 3 patents, the key one being US10076494, 'Stable orally disintegrating pharmaceutical compositions', impacting the release of generic versions of Omeprazole. This pivotal patent will expire on 08 December, 2036. Below are the details of the patent: